Outcome of Preserved Mitral Valve Apparatus During Mitral Valve Replacement

NCT ID: NCT05438433

Last Updated: 2022-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-28

Study Completion Date

2021-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Are there differences in outcome of mitral valve replacement with preservation of mitral apparatus among rheumatic and/or ischemic mitral lesions?.

Mitral valve replacement with preservation of leaflets, and added coronary artery-bypass surgery, when indicated, is it a feasible and reproducible procedure?.

The study was designed to compare outcome after prosthetic mitral replacement with preservation of mitral apparatus for rheumatic valve disease with outcome of replacement for ischemic myocardium and mitral valve disease, The outcomes will be guided by clinical assessment. and echo-cardiograph.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives: The aim is to compare outcome of modified preservation of mitral valve apparatus during prosthetic mitral replacement for rheumatic versus myocardial ischemia \&mitral valve disease.

Methods ;This prospective cross-sectional comparative study will include 50 patients with isolated rheumatic mitral valve disease (group A) and 50 patients with mitral disease and myocardial ischemia (group B), surgery is expected to be performed between 2017 and 2020 at one center. All patients will have modified preservation of mitral apparatus during prosthetic mitral replacement. Additionally, group B patients will have bypass grafts to left anterior descending and/or posterior descending / right coronary artery. Data will be collected and analyzed.

The Institutional Review Board (IRB), Ethics Committee (EC)-approval and consent of each patient were obtained.

Criteria for inclusion of patients and exclusion of others were determined according to the guide lines.

Statistical analysis::

Qualitative variables and their association among both groups were studied by applying Chi-square test and Fisher Exact test. Quantitative variables among both groups were compared by applying independent samples t-test. P \< 0.05 values mean statistically-significant results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diseases of Mitral Valves Abnormality of Mitral Valve Annulus (Disorder) Mitral Valve Replacement

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

: Preservation of mitral apparatus , mitral valve replacement Rheumatic valve disease and ischemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

both groups of patients received surgical treatment parallel to each other.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

All roles were unmasked

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

50 patients with isolated rheumatic mitral valve disease (group A)

Group Type SHAM_COMPARATOR

St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets

Intervention Type DEVICE

St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts

Group B

50 patients with mitral disease and myocardial ischemia (group B)

Group Type OTHER

St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets

Intervention Type DEVICE

St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

St.Jude bi leaflet prosthetic mitral valve to replace the diseased valve with preservation of both leaflets

St.Jude prosthetic(FDA approved) mitral valve replacement with or without coronary artery bypass grafts

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

St.Jude bi leaflet prosthesis to replace diseased valve with preservation of leaflets with Myocardial re-vascularization St.Jude prosthetic mitral replacement with preservation of valve apparatus and bypass grafts for associated coronary artery disease

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Mitral stenosis (MS)

* symptoms are severely limiting and cannot be managed with diuresis and heart rate control.

Mitral regurgitation(MR):

\* acute severe MR require surgical correction for hemo-dynamics and relief of symptoms .

Chronic primary mitral regurgitation:

\* rheumatic heart disease: replacement before irreversible changes occur can be curative.

Mixed Mitral Stenosis and Mitral Regurgitation:

* If beta blockers and diuretics do not relieve symptoms, replacement should be performed only in patients who have severe limiting symptoms.
* Myocardial ischemia associating or complicated with miral valve disease.

Exclusion Criteria

* Patients showing good response to medical therapy, and Cases complicated by:
* ineffective endocarditis,
* previous myocardial re-vascularization
* ischemic ventricular septal defect,
* left ventricular aneurysm,
* Ruptured papillary muscles of mitral apparatus.
Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Research Centre, Egypt

OTHER

Sponsor Role collaborator

Suez Canal University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hamdy Dosoky Ibraheem Elayouty

Prof. of Cardio-thoracic Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohamed A. allaban, PhD

Role: STUDY_DIRECTOR

Suez Canal University, FOM- Research Ethics Committee

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Suez Canal University

Ismailia, , Egypt

Site Status

Suez Canal University

Ismailia, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2796#

Identifier Type: -

Identifier Source: org_study_id